Market research
NV4P.F Cellectar Biosciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 5.58
- Dividend yield
- 0.0%
- Beta
- 1.47
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 5.58
- Dividend yield
- 0.0%
- Beta
- 1.47
About
About Cellectar Biosciences, Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NV4P.F discussion.
5 years, 5 months ago
Cellectar Biosciences, Inc is currently in a long term downtrend where the price is trading 29.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cellectar Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 7.0% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 44.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Cellectar Biosciences, Inc gets an overall score of 1/5.